期刊文献+

多烯磷脂酰胆碱治疗慢性乙型肝炎合并脂肪肝损害临床疗效观察 被引量:1

Clinical study on the treating of chronic hepatitis B complicated by fatty liver with polyunsaturated phosphatidyl choline phthalate
下载PDF
导出
摘要 目的:观察多烯磷脂酰胆碱治疗慢性乙型肝炎合并脂肪肝损害的临床疗效。方法:选择确诊慢性乙型肝炎合并脂肪肝损害63例;随机分为两组。治疗组(n=33)在常规保肝治疗的基础上,加服多烯磷脂酰胆碱胶囊,456mg/次,每日3次;对照组(n=30)常规保肝治疗;两组均4周为1个疗程。结果:两种药物临床总有效率分别为93.9%、66.7%,血清胆红素下降及肝功能恢复治疗组较对照组明显(P<0.05)。结论:多烯磷脂酰胆碱治疗慢性乙型肝炎合并脂肪肝损害,能取得较为满意的疗效,未见明显副作用。 Objective:To discuss the results of treating chronic hepatitis B complicated by fatty liver with polyunsaturated phosphatidyl choline phthalate.Methods:63 cases of chronic hepatitis B patients were selected and divided at random into two groups. The treatment group(n=33) in the conventional treatment based on liver protection,plus clothing polyene phosphatidyl choline capsules phthalate,456 mg /times,three times a day;the control group(n=30) conventional liver treat ment;two groups were four weeks as a course of treatment.Results:Two kinds of drugs of clinical total effective rates were 93.9%,66.7%,decline in serum bilir-ubin and liver function to restore the treatment group than in the control group was significantly(P〈0.05) .Conclusion:It is efficacy and safety of polyunsaturated phosphatidyl-PC treatment of chronic hepatitis B complicated by fatty liver injury in clinical treatment,no obvious side effects.
作者 段树鹏
出处 《中国当代医药》 2009年第25期41-42,共2页 China Modern Medicine
关键词 多烯磷脂酰胆碱 慢性乙型肝炎合并脂肪肝 肝功能 Polyunsaturated phosphatidyl-PC Chronic hepatitis B complicated by fatty liver disease Liver function
  • 相关文献

参考文献6

二级参考文献39

  • 1王莉.慢性肝炎的分类——诊断、分级、分期[J].国外医学(消化系疾病分册),1995,15(2):100-102. 被引量:1
  • 2王家良 刘鸣.循证医学[M].北京:人民卫生出版社,2001.177-188.
  • 3Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology, 1981; 1(3): 43.
  • 4Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary[J]? Control Clin Trials, 1996; 17(34): 1-12.
  • 5Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J]. JAMA, 1995; 273(5): 408-412.
  • 6Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta-analyses[J]? Lancet,1998; 352(9128): 609-613.
  • 7Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses[J]. Annals of Internal Medicine, 2001; 135(11) : 982-989.
  • 8Perter J, Jenkins BP, Portmann A.L, Eddleston W.F, Roger Williams. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double blind controlled trial[J]. Liver, 1982; 2(3): 77-81.
  • 9Kordac V, Brodanova M, Marecek Z, Jirasek AP. Essentiale forte in the treatment of chronic active hepatitis[J]. Prakt Lek (Praha), 1985; 65(43): 834-837.
  • 10Niederau C, Strohmeyer G, Heintges T, Peter K, Gopfert E (Leich Study Group). Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double blind, placebo controlled trial[J]. Hepato-Gastroenterology, 1998; 45(21): 797-804.

共引文献14133

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部